Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Coeptis Therapeutics Holdings, Inc. (COEP : NSDQ)
 
 • Company Description   
Coeptis Therapeutics Holdings Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer. Coeptis Therapeutics Holdings Inc., formerly known as Bull Horn Holdings Corp., is based in WEXFORD, Pa.

Number of Employees: 7

 
 • Price / Volume Information   
Yesterday's Closing Price: $15.13 Daily Weekly Monthly
20 Day Moving Average: 87,301 shares
Shares Outstanding: 5.34 (millions)
Market Capitalization: $80.80 (millions)
Beta: -0.53
52 Week High: $21.41
52 Week Low: $2.31
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 6.93% 5.52%
12 Week 20.56% 17.11%
Year To Date 175.09% 151.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
105 BRADFORD ROAD SUITE 420
-
WEXFORD,PA 15090
USA
ph: 724-934-6467
fax: -
ir@coeptistx.com https://coeptistx.com
 
 • General Corporate Information   
Officers
David Mehalick - Chief Executive Officer; Chairman and President
Daniel Yerace - Director and Vice President of Operations
Brian Cogley - Chief Financial Officer
Christine Sheehy - Vice President of Compliance and Secretary
Christopher Calise - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 19207A207
SIC: 6199
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/26/26
Share - Related Items
Shares Outstanding: 5.34
Most Recent Split Date: 12.00 (0.05:1)
Beta: -0.53
Market Capitalization: $80.80 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/26/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.68
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 42.00%
vs. Previous Quarter: 50.43%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 17.91%
ROE
09/30/25 - -173.32
06/30/25 - -201.73
03/31/25 - -282.39
ROA
09/30/25 - -104.29
06/30/25 - -108.46
03/31/25 - -127.23
Current Ratio
09/30/25 - 2.21
06/30/25 - 0.83
03/31/25 - 0.82
Quick Ratio
09/30/25 - 2.21
06/30/25 - 0.83
03/31/25 - 0.82
Operating Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Net Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Pre-Tax Margin
09/30/25 - -2,727.94
06/30/25 - -4,771.59
03/31/25 - -17,931.75
Book Value
09/30/25 - 2.26
06/30/25 - 1.70
03/31/25 - 2.22
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - 0.01
06/30/25 - 0.02
03/31/25 - 0.02
Debt-to-Capital
09/30/25 - 1.36
06/30/25 - 2.07
03/31/25 - 1.97
 

Powered by Zacks Investment Research ©